Clinical Trial

Treatment of Breast Cancer

Study Description

Copper (Cu) 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer

This phase II trial studies how well copper Cu64-DOTA-trastuzumab positron emission tomography (PET) works in predicting response to treatment with trastuzumab and pertuzumab before surgery in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread from where it started to nearby tissue or lymph nodes. Diagnostic procedures, such as copper Cu 64 DOTA-trastuzumab PET, may help predict a patient's response to trastuzumab and pertuzumab before surgery in patients with locally advanced HER2 positive breast cancer.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Radiation - Copper Cu 64-DOTA-Trastuzumab

Given IV

Laboratory Biomarker Analysis

Correlative studies

Biological - Pertuzumab

Given IV

Procedure - Positron Emission Tomography

Undergo PET

Procedure - Therapeutic Conventional Surgery

Undergo surgery

Biological - Trastuzumab

Given IV

Additional Information

Official Study Title

Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzumab-Based Neoadjuvant Therapy

Clinical Trial ID

NCT02827877

ParticipAid ID

ZdPGAb